Navigation Links
Vanda Pharmaceuticals Reports Third Quarter 2008 Results
Date:10/30/2008

5,190,460) (57,990,702)

Interest income 323,476 1,514,708 1,630,238 4,608,143

Other income - 71,345 - 71,345

Total other

income, net 323,476 1,586,053 1,630,238 4,679,488

Loss before tax

provision (10,869,211) (21,935,841) (43,560,222) (53,311,214)

Tax provision - 7,660 - 10,070

Net loss $(10,869,211) $(21,943,501) $(43,560,222) $(53,321,284)

Basic and diluted

net loss per share

attributable to

common

stockholders $(0.41) $(0.82) $(1.63) $(2.03)

Shares used in

calculation of

basic and diluted

net loss per share

attributable to

common

stockholders 26,650,534 26,612,853 26,649,439 26,223,151

VANDA PHARMACEUTICALS INC.

(A Development Stage Enterprise)

CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited)

September 30, 2008 December 31, 2007

ASSETS

Current assets:

Cash and cash equivalents $41,438,719 $41,929,533

Marketable securities 10,224,854 43,243,960

Prepaid expenses, deposits and

other current assets 2,942,703 1,781,881

Total current assets 54,606,276 86,955,374

Marketable securities, long-term - 7,979,331

Property and equipment, net 1,885,775 1,345,845

Deposits 150,000 150,000

Restricted cash 430,230 430,230

Total assets $57,072,281 $96,860,780
'/>"/>

SOURCE Vanda Pharmaceuticals Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2007 Results
2. Vanda Pharmaceuticals to Present at the Bank of America 2008 Healthcare Conference
3. LabCorp(R) and Vanda Pharmaceuticals Collaborate to Offer Genetic Tests
4. Vanda Pharmaceuticals to Announce Second Quarter 2008 Financial Results on August 5, 2008
5. Vanda Pharmaceuticals Declares Dividend Distribution of Preferred Stock Purchase Rights
6. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
7. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
8. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
9. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
10. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
11. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 15, 2014 A study has been launched ... Formula 1 track could help to tackle the problem of ... Stowhealth (a GP surgery based in Stowmarket) and academics at ... Telemetry technology, which is inspired by equipment used ...
(Date:1/15/2014)... 2014 The Microcompetition with Foreign DNA theory ... of these latent viruses is the Epstein Barr Virus (EBV), ... arthritis (RA) is a chronic inflammatory disease that destroys the ... that RA patients have high concentrations of EBV DNA in ...
(Date:1/15/2014)... Freeslate, Inc ., the leading ... Lupin Limited, one of India’s top five pharmaceutical companies, ... System for high throughput solid form screening. ... a wide range of quality, affordable generic and branded ...
(Date:1/14/2014)... 2014 Date: Friday, April 11, 2014 , ... Club, 1360 Almshouse Road, Warrington, Pa. , Details: ... dedicated to finding a cure for hepatitis B and improving ... its annual Crystal Ball on Friday, April 11 at Warrington ...
Breaking Biology Technology:Formula 1 Technology Tackles Obesity in Unique Healthcare Partnership 2Formula 1 Technology Tackles Obesity in Unique Healthcare Partnership 3Formula 1 Technology Tackles Obesity in Unique Healthcare Partnership 4Study: Rheumatoid Arthritis (RA) Patients Have EBV; The CBCD Says this is Consistent with Microcompetition 2Study: Rheumatoid Arthritis (RA) Patients Have EBV; The CBCD Says this is Consistent with Microcompetition 3Lupin Selects Freeslate’s CM Protégé PharmD System to Accelerate Polymorph Screening for Drug Development 2Lupin Selects Freeslate’s CM Protégé PharmD System to Accelerate Polymorph Screening for Drug Development 3Hepatitis B Foundation to Host Annual Crystal Ball Gala 2
... 17 Kensey Nash Corporation,(Nasdaq: KNSY ) ... Annual Palm,Beach Emerging Growth Institutional Investor Forum at ... 23, 2008., Wendy F. DiCicco, Kensey Nash,s ... 9:05 a.m. (ET). The presentation,materials will be available ...
... 17 Wyeth Consumer Healthcare, a,division of Wyeth (NYSE: ... (FDA) decision to no longer recommend use of,over-the-counter cough ... "This decision is consistent with our voluntary removal in ... the global market,to help reduce dosing errors and overdoses ...
... CAMBRIDGE, Mass., Jan. 17 Peptimmune, Inc., a ... a first close,of $8.2 million of a Series ... by New Enterprise Associates, MPM Capital, Hunt Ventures,L.P., ... as well as,certain other investors, including its Chairman ...
Cached Biology Technology:Wyeth Consumer Healthcare Supports U.S. Food and Drug Administration Decision for Over-the-Counter Cough and Cold Medications in Children under Two Years of Age 2Wyeth Consumer Healthcare Supports U.S. Food and Drug Administration Decision for Over-the-Counter Cough and Cold Medications in Children under Two Years of Age 3Peptimmune Announces First Close of Series D Private Financing 2Peptimmune Announces First Close of Series D Private Financing 3
(Date:4/17/2014)... in France have hit on a novel method ... the correct and most effective treatment possible., Kidney ... western and developing world. If left untreated, apart ... renal failure and other complications. In many patients ... Clearly a more effective pathological approach to diagnosis ...
(Date:4/17/2014)... in the Cell Press journal Current Biology ... rather novel sex lives. The Brazilian insects, which represent ... Neotrogla , are the first example of an animal ... been identified in several different animals, Neotrogla ... is also reversed," says Kazunori Yoshizawa from Hokkaido University ...
(Date:4/17/2014)... of Texas Medical Branch at Galveston are the ... radiation for cervical cancer should begin colorectal cancer ... UTMB researchers, finding a high incidence of secondary ... radiation, offer new recommendations that the younger women ... eight years after their initial cervical cancer diagnosis ...
Breaking Biology News(10 mins):In sex-reversed cave insects, females have the penises 2Radiation therapy for cervical cancer increases risk for colorectal cancer 2
... with hydrocephalus, or "water on the brain" must have shunts ... reduce harmful pressure. While shunts do their job ... high for a variety of reasons, which requires putting the ... it more hospital time, potential additional neurological complications and an ...
... growing demand for bio-fuels and hydro-electricity due to high ... to the preservation of precious wetlands worldwide as farmers ... crop plantations and hydro dams. However, resisting pressures ... that provide a suite of services essential to humanity, ...
... embedded with a telescope promise to make it easier ... other activities requiring sharper distance vision. Schepens Eye Research ... over earlier devices in an article published in the ... mailed in print form to subscribers this month. ...
Cached Biology News:Antimicrobial sutures reduce infections in brain shunt surgery, study finds 2Rising energy, food prices major threats to wetlands as farmers eye new areas for crops 2Rising energy, food prices major threats to wetlands as farmers eye new areas for crops 3Telescope embedded in glasses lens promises to make driving easier for visually impaired 2Telescope embedded in glasses lens promises to make driving easier for visually impaired 3
This bispecific antibody complex has been tested for efficient depletion of CD41+ cells using the StemSep ; negative immunomagnetic cell separation system....
... The Eclipse C1 Plus is a ... highest-quality digital imaging with an ultra-compact and ... of the C1 Plusboost optical performance to ... acquisition.The system alsoincludes support for X and ...
... is an integrated digital microscope and camera ... equipment setup, optical adjustment or software installation. ... technology, COOLSCOPE combines simplicity and advanced technology ... offers simultaneous viewing of a macro image ...
... The TUNEL-based assay kit provides ... control cells for convenient detection of ... tissue sections. The incorporation of BrdU ... than biotinylated or digoxigenylated methods. Results ...
Biology Products: